Co-Authors
This is a "connection" page, showing publications co-authored by Assiamira Ferrara and Laurel Habel.
Connection Strength
2.229
-
Pioglitazone Use and Risk of Bladder Cancer--Reply. JAMA. 2015 Dec 15; 314(23):2568-9.
Score: 0.549
-
Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013 Dec; 36(12):3953-60.
Score: 0.473
-
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011 Apr; 34(4):923-9.
Score: 0.396
-
A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus. Cancer Epidemiol Biomarkers Prev. 2018 05; 27(5):525-530.
Score: 0.162
-
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015 Jul 21; 314(3):265-77.
Score: 0.133
-
Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila). 2015 Feb; 8(2):174-9.
Score: 0.129
-
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):636-45.
Score: 0.122
-
Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology. 2008 Dec; 135(6):1914-23, 1923.e1.
Score: 0.083
-
Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):628-35.
Score: 0.080
-
Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf. 2007 Nov; 16(11):1195-202.
Score: 0.078
-
Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2010 Dec; 19(12):3027-36.
Score: 0.024